Financial Advocates Investment Management Salarius Pharmaceuticals, Inc. Transaction History

Financial Advocates Investment Management

4 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2022 May 11, 2022	BUY	$0.34 - $0.54 $3,900 - $6,194	11,472 New	11,472 $5,000
Q4 2021 Feb 14, 2022	SELL	$0.49 - $1.01 $5,621 - $11,586	-11,472 Closed	0 $0
Q4 2019 Feb 13, 2020	SELL	$3.02 - $5.9 $31,106 - $60,770	-10,300 Reduced 47.31%	11,472 $43,000
Q3 2019 Nov 13, 2019	BUY	$5.28 - $20.25 $114,956 - $440,883	21,772 New	21,772 $119,000

Ticker SLRX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 2,244,650
Market Cap $5.43M
Description
Salarius Pharmaceuticals, Inc., a clinical-stage biotechnology company, focuses on developing epigenetic-based cancer treatments. Its lead candidate is Seclidemstat (SP-2577), a small molecular inhibitor which is in Phase I/II clinical trial for the treatment of advanced solid tumors, as well as Ewing sarcoma. The company also offers SP-3164, a ...

Get notified when there are updates to the investment portfolio of Financial Advocates Investment Management, based on Form 13F filings with the SEC.

Stay updated on Financial Advocates Investment Management with notifications on news.